By IGHI guest blogger Chanice Henry, Editor, Pharma IQ & Pharma Logistics IQ
Similar to new Hollywood feature Rampage, a recent study has urged the life sciences industry not to underestimate the dangers that could hide within CRISPR Cas9.
Although the film has been criticised for wildly exaggerating the capabilities of the gene editing technique, it can be recognised for its effort to draw focus from the excitable buzz around CRISPR Cas9 towards the importance of considering the ethics and dangers associated with the tool.
A recent commentary piece also emphasised the importance of methodically debating the potential outcomes of CRISPR within the task of tackling Malaria.
By Dr Michael Templeton, Faculty of Engineering, Department of Civil and Environmental Engineering, Imperial College London
With World Water Day approaching on 22 March, research at Imperial College London is highlighting yet another example of why access to clean water is so vitally important to human health.
The research is seeking to quantify the role of access to clean water in reducing the odds of becoming infected with the neglected tropical disease schistosomiasis.
It has been estimated that 200 million people in developing countries are infected with the parasite causing this disease, which manifests itself in a range of symptoms, including enlargement of the liver and spleen, anaemia, increased risk of bladder cancer, exacerbation of the transmission of HIV and its progression to AIDS, and in extreme cases seizures.
By Professor Alan Fenwick OBE, Director of SCI (Schistosomiasis Control Initiative), Imperial College, London)
Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes, in subtropical and tropical regions worldwide. It is also known as bilharzia.
The Schistosomiasis Control Initiative (SCI) at Imperial College London supports Ministries of Health and Education in 16 countries to deliver medicines to treat people infected with schistosomiasis and three intestinal worms. The medicines are donated by various pharmaceutical companies, Merck KgGA (praziquantel), GSK (albendazle) and Johnson and Johnson (mebendazole), and for the most part, the targets are school aged children.